Comparative Pharmacology
Head-to-head clinical analysis: LATANOPROST versus YUVEZZI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LATANOPROST versus YUVEZZI.
LATANOPROST vs YUVEZZI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Latanoprost is a prostaglandin F2α analogue that acts as a selective FP receptor agonist. It increases uveoscleral outflow of aqueous humor by binding to prostanoid FP receptors in the ciliary muscle, leading to matrix metalloproteinase activation and remodeling of the extracellular matrix, thereby reducing intraocular pressure.
YUVEZZI is not a recognized drug. No mechanism available.
Instill one drop (1.5 mcg) of 0.005% ophthalmic solution into the affected eye(s) once daily in the evening.
150 mg orally twice daily
None Documented
None Documented
Terminal half-life of latanoprost acid is 17 minutes (0.28 hours) systemically; clinically, intraocular pressure reduction persists for 24 hours due to prolonged receptor binding.
Clinical Note
moderateLatanoprost + Unoprostone
"Latanoprost may increase the hypotensive activities of Unoprostone."
Clinical Note
moderateLatanoprost + Hydrochlorothiazide
"Latanoprost may increase the hypotensive activities of Hydrochlorothiazide."
Clinical Note
moderateTiaprofenic acid + Latanoprostene bunod
"The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Tiaprofenic acid."
Clinical Note
moderateCarprofen + Latanoprostene bunod
Terminal elimination half-life of 8–12 hours; permits twice-daily dosing in most indications
Renal: 88% (metabolites); fecal: 6% (metabolites); unchanged latanoprost is not excreted renally.
Renal: 70% unchanged; biliary/fecal: 30% as metabolites
Category A/B
Category C
Prostaglandin Analog
Prostaglandin Analog
"The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Carprofen."